Loading...

Home
ETF
AKTX

AKTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

AKTX News

Akari Therapeutics Highlights 2025 Progress, Plans First-in-Human Trials in 2026

Jan 09 2026Globenewswire

Akari Therapeutics Presents ADC Platform and 2026 Strategic Priorities at Biotech Showcase

Jan 08 2026Globenewswire

Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%

Dec 31 2025Benzinga

Akari Therapeutics Advances Novel Antibody Drug Conjugates with Significant Achievements in 2025

Dec 30 2025Newsfilter

Akari Therapeutics Highlights 2025 Progress and Future Plans

Dec 30 2025Globenewswire

Akari Initiates GMP Manufacturing for AKTX-101 Antibody-Drug Conjugate

Dec 24 2025NASDAQ.COM

Akari Therapeutics Issues 12.6M ADSs Raising $5M for Oncology Development

Dec 16 2025Newsfilter

Akari Therapeutics Advances Novel ADCs, Plans Clinical Trials for AKTX-101 in Q4 2026

Dec 04 2025Globenewswire

Akari Therapeutics Names Kameel D. Farag as Interim CFO, Bringing Biotech Finance Expertise

Nov 18 2025Newsfilter

Teradata Shares Surge Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

Nov 05 2025Benzinga

Akari Therapeutics' Accepted Abstract Highlights Innovative Splicing-Targeted ADC Payload That Promotes Immune Activation

Nov 04 2025Newsfilter

Akari Therapeutics Establishes Scientific Advisory Board and Welcomes Esteemed Medical Oncologist Sara A. Hurvitz, MD, FACP, as First Member

Oct 30 2025Newsfilter

Akari Therapeutics Unveils New CEO Corner Platform

Oct 22 2025Newsfilter

Akari Therapeutics Submits Two New Patents for Immuno-Oncology Mechanism of Action in Innovative ADC Platform Featuring Spliceosome Modulating Payload PH1

Oct 09 2025Newsfilter

Akari Therapeutics Reveals Acceptance of Abstract for Oral Presentation at the 40th Annual SITC Meeting

Oct 03 2025Newsfilter

Akari Therapeutics' Preclinical Findings Highlight the Promise of Its Innovative ADC Spliceosome Modulating Agent, PH1

Sep 24 2025Newsfilter